Optomed Oyj — AGM Information 2021

Jan 14, 2021

Proposal of Optomed’s Nomination Board

Proposal of Optomed’s Nomination Board

Optomed Plc         Stock Exchange Release    14 January 2021 at 8:00, Helsinki

Proposal of Optomed’s Nomination Board

Optomed’s Nomination Board proposes the following to the next Annual General
Meeting:

Number of Board members

The Nomination Board proposes, that the number of members of the Board of
Directors for the term expiring at the end of the Annual General Meeting 2022 is
five.

Composition of the Board of Directors

The Nomination Board proposes to the Annual General Meeting that:

· Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam are re
-elected as Board members
· Haohao Zhang is elected as a new Board member

Jun Wu has informed the Nomination Board that he is not available for re
-election-to the Board.
Haohao Zhang (MD, Ph.D, born 1982, a PRC citizen) is an Executive Director of
Cenova Capital. Prior to Cenova, Dr. Zhang was the Executive Scientific
Assistant to the CEO of Shanghai Biomabs Pharmaceutical Co. Ltd., one of the
leading antibody drug companies in China. Dr. Zhang received her Ph.D. in
Oncological Pharmacology from the Shanghai Institute of Materia Medica, Chinese
Academy of Sciences and her M.D. with honors from the Medical School of Jinan
University, Guangzhou. She is independent of Optomed and dependent of a major
shareholder.

Proposal for the remuneration of the Board of Directors

The Nomination Board proposes to the Annual General Meeting that the annual
remuneration payable to the members of the Board of Directors to be elected at
the Annual General Meeting for the term until the end of the Annual General
Meeting in 2022 to be as follows:

· EUR 36,000 for the Chairman of the Board
· EUR 18,000 for each Board member

In addition, the Nomination Board proposes that a meeting fee in the amount of
EUR 500 is paid to the Audit Committee chairman for each Audit Committee
meeting. The Shareholders’ Nomination Board proposes that 40 % of the Board
remuneration is paid in Optomed shares and 60 % in cash. The remuneration will
be paid once a year in August, after Optomed’s H1 report has been announced.

Nomination Board

Optomed’s nomination board consists of the following individuals:

· Hai Wu (appointed by Cenova Capital (China))
· Jarmo Malin (appointed by Aura Capital Oy)
· Ingo Ramesohl (appointed by Robert Bosch Venture Capital GmbH)

Petri Salonen (chairman of Optomed’s Board of Directors) serves as the
Nomination Board's expert member and Jarmo Malin acts as the chairman of the
Nomination Board.

Optomed Plc

Further enquiries

Jarmo Malin, Chairman of the Nomination Board, jarmo.malin@auratum.com

Sakari Knuutti, secretary of the Nomination Board, Optomed Plc,
sakari.knuutti@optomed.com

Optomed in Brief

Optomed is a Finnish medical technology company and one of the leading providers
of handheld fundus cameras. Optomed combines handheld cameras with software and
artificial intelligence with the aim to transform the diagnostic process of
blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its
business Optomed focuses on eye-screening devices and software solutions related
R&D in Finland and sales through different channels in over 60 countries. The
company has an extensive portfolio of 55 international patents protecting the
technology. In 2019, Optomed’s revenue reached EUR 15 million and at the end of
2019 Optomed employed 100+ professionals.